Exhibit 99.1 Veracyte Announces First Quarter 2025 Financial Results Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2025 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by stron ...

Core Insights - Veracyte (VCYT) is experiencing growth driven by its Afirma and Decipher tests, with expectations for continued expansion in the coming years [1][6] - The company has outperformed the industry and S&P 500, with a market capitalization of $2.48 billion and an earnings yield of 3.9% [2] - Despite strong performance, Veracyte faces challenges from declining biopharmaceutical revenues and macroeconomic factors [9][10] Afirma Test Performance - The Afirma solution has shown resilience, with over 16,300 tests delivered in Q4, an 8% year-over-year increase [3] - Revenue growth of 4% is attributed to deeper market penetration and new customer acquisitions [3] - A significant milestone was achieved with expanded Medicare reimbursement for Bethesda V thyroid nodules, leading to an 80% year-over-year revenue increase for these cases [4] Decipher Test Growth - The Decipher Prostate Cancer tests have seen substantial growth, with Q4 recording 22,400 tests, a 45% increase year-over-year [5] - The test is the only NCCN-recommended gene expression test for prostate cancer treatment decisions, enhancing its market position [5] - Recent approvals for metastatic assessment and New York State clearance are expected to further boost Decipher's growth [6] Long-Term Growth Strategies - Veracyte is focused on long-term growth through identifying medical needs, developing tests, and securing clinical evidence [7] - The NIGHTINGALE study for nasal swab diagnostics is progressing well, with over 85% of the target enrollment completed [7] - The company plans to launch its first MRD indication targeting muscle-invasive bladder cancer in the first half of 2026 [7] Financial Performance and Estimates - The Zacks Consensus Estimate for Veracyte's 2025 earnings per share has increased by 34.8% to $1.24, with revenues projected at $488.7 million, a 9.6% rise from the previous year [11]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score emphasizes a company's financial health and future growth potential [4] - Momentum Score focuses on stocks with upward or downward price trends [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [9] Stock Recommendation: Veracyte (VCYT) - Veracyte is a diagnostics company specializing in cancer detection and treatment, with a diverse portfolio of genomic tests [12] - VCYT holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of B, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 4.2% for the current fiscal year, with upward revisions in earnings estimates [13] - VCYT's average earnings surprise stands at 515.9%, making it a compelling option for growth investors [13][14]

After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term moving ...

It has been about a month since the last earnings report for Veracyte (VCYT) . Shares have added about 0.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Summary of Key Points Core Viewpoint - Veracyte (VCYT) shows potential for significant upside based on Wall Street analysts' short-term price targets, with a mean target of $45.50 indicating a 35.1% upside from the current price of $33.69 [1]. Price Targets and Estimates - The average of 10 short-term price targets ranges from a low of $29 to a high of $55, with a standard deviation of $7.60, indicating variability in analysts' estimates [2]. - The lowest estimate suggests a decline of 13.9%, while the most optimistic estimate indicates a 63.3% upside [2]. - Analysts' consensus on price targets should be approached with caution, as their ability to set unbiased targets has been questioned [3][7]. Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding VCYT's earnings prospects supports the view of potential upside, as indicated by positive revisions in earnings estimates [4][11]. - Over the past 30 days, three earnings estimates have been revised higher, leading to an 11.8% increase in the Zacks Consensus Estimate for the current year [12]. - VCYT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13]. Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8]. - A low standard deviation in price targets indicates a high degree of agreement among analysts about the stock's price movement direction, serving as a starting point for further research [9]. - While price targets should not be the sole basis for investment decisions, they can provide useful directional guidance [10].

Core Viewpoint - Veracyte (VCYT) has demonstrated strong performance with a 45.6% increase in share price over the past year, significantly outperforming the industry and S&P 500, driven by the success of its Afirma and Decipher tests [1][3]. Company Overview - Veracyte, based in San Francisco, CA, specializes in advanced genomic tests that enhance diagnostic and treatment decisions for cancer and other diseases, aiming to reduce unnecessary procedures and expedite treatment [2]. Key Growth Catalysts - The growth in Veracyte's share price is attributed to the strong performance of Afirma and Decipher tests, with Afirma test volumes increasing by 12% in 2024 and 8% year-over-year in Q4, driven by deeper market penetration and new customer acquisition [3] - Decipher has been recognized in the updated 2025 NCCN guidelines as a leading gene expression test for personalized prostate cancer treatment, achieving a remarkable 45% year-over-year volume growth in Q4 [4] - Veracyte is expanding its testing capabilities to cover the entire prostate cancer risk spectrum, with plans to launch into this expanded market in the first half of 2025 [5]. Financial Estimates - The Zacks Consensus Estimate for Veracyte's 2025 earnings per share (EPS) is $1.00, with projected revenue growth of 9.5% to $486.2 million in 2025 and further growth to $533.7 million in 2026, an increase of 9.3% [9].

Revenue and Reimbursement - A significant portion of the company's revenue is derived from a limited number of third-party payers, with fluctuations expected as reimbursement policies change [170]. - Medicare reimbursement rates for the Afirma GSC classifier are set at $3,600, while Decipher Prostate has a reimbursement rate of $3,873, and Decipher Bladder is priced at $3,469.83 [175]. - The company anticipates that achieving coverage and reimbursement for its tests will take several years, with ongoing payer consolidation creating uncertainty [180]. - Changes in Medicare payment rates could lead to decreased reimbursement from commercial payers, impacting overall revenue [171]. - Increased patient cost-sharing and economic pressures may lead to reduced demand for the company's tests [186]. - The company is focused on increasing adoption and reimbursement for its existing tests, including Decipher Prostate, Afirma, and Decipher Bladder [180]. - Future healthcare initiatives may lead to decreased revenue and lower reimbursement rates for tests, adversely affecting the company's financial condition [213]. - Clinical laboratory services are currently excluded from Medicare Part B co-insurance and co-payment as preventative services, but changes could increase costs and reduce collections [214]. - The Inflation Reduction Act of 2022 may impose government-established pricing and rebates on certain products, affecting revenue [216]. Regulatory Compliance and Challenges - Compliance with federal and state licensing requirements is essential; failure to maintain these could disrupt testing services and revenue [187]. - The company’s future growth depends on successfully adapting its diagnostic tests as IVDs and securing necessary regulatory approvals for international markets [196]. - The company has experienced quality, regulatory, or manufacturing irregularities, particularly at its Marseille facility, which may affect its operational capabilities [194]. - The FDA's final rule under 21 CFR Part 809 will phase out enforcement discretion for laboratory developed tests (LDTs) over four years, potentially increasing regulatory requirements [227]. - Non-compliance with FDA regulations could result in enforcement actions, adversely affecting the company's financial condition and operations [233]. - The process of obtaining FDA marketing authorization, including PMA and 510(k) clearance, is lengthy, costly, and uncertain, potentially taking several months to years [237]. - The company is subject to ongoing regulatory requirements, including compliance with ISO 13485 and FDA regulations, which could significantly impact operations if not adhered to [253]. - Recent FDA rule changes aim to align QSR with ISO 13485:2016, potentially increasing compliance costs and operational risks [254]. - The company may incur significant expenditures to comply with stricter EU regulations, impacting its ability to market products in the EU and EEA [243]. - The company is dependent on third-party technology providers to maintain compliance with regulatory requirements, which poses risks to obtaining necessary clearances [252]. Competition and Market Position - The company faces competition in genomic testing from firms like Myriad Genetics and MDx Health, which could affect market share and revenue growth [256]. - The Decipher Prostate test competes with traditional pathology methods and emerging technologies, necessitating continuous innovation to maintain market position [256]. - The Afirma genomic classifier faces competition from organizations using NGS technology, highlighting the need for differentiation in product offerings [257]. - The company anticipates competition in the lung cancer diagnostics market from Biodesix, Inc., and in breast cancer diagnostics from Exact Sciences Corporation, which holds a significant market share [258]. Operational and Financial Risks - The company faces challenges in maintaining demand for its tests, which is critical for sustaining profitability [181]. - The company relies on sole suppliers for critical reagents and materials, which poses risks to revenue generation if these suppliers fail to meet quality or quantity requirements [200]. - The integration of C2i may face challenges, including potential flaws in algorithms and the need for substantial internal control improvements, which could incur significant costs [194]. - The company must effectively manage inventory to avoid adverse impacts on operations, as supply chain issues and expiration of materials could lead to increased costs [198]. - The company’s ability to scale operations and meet demand is critical, requiring additional certified laboratory scientists and enhanced quality assurance programs [207]. - Legislative changes in the U.S. healthcare system may materially affect the company’s financial condition and operations, particularly regarding reimbursement for tests [209]. - The company is actively participating in the bankruptcy proceedings of NanoString, which may disrupt supply chains and impact operational stability [203]. - The company is facing adverse impacts from uncertain economic conditions, including persistent inflation and volatile interest rates, which have been exacerbated by global conflicts such as the war in Ukraine [359]. - The company has experienced disruptions in its operations due to geopolitical uncertainties and natural disasters, which could affect supply and demand for its products [361]. Intellectual Property and Litigation - The company relies on patent protection for its proprietary technologies, but the patent application process can be time-consuming and expensive, posing risks to competitive advantage [316]. - The patent positions in the life sciences sector are uncertain, and recent court decisions may affect the patentability of genomic diagnostic tests [321]. - The company may face challenges in enforcing its intellectual property rights, particularly in foreign jurisdictions where protections may be weaker [322]. - The company may incur significant costs and distractions from litigation related to intellectual property rights, which could adversely affect its business [331]. - The licensing of third-party technology is competitive, and failure to secure necessary licenses on reasonable terms could harm the company's business [336]. - The company may be involved in litigation related to third-party intellectual property, which could be costly and impact its financial condition [338]. Financial Performance and Taxation - As of December 31, 2024, the company had net operating loss (NOL) carryforwards of approximately $605.4 million for federal tax purposes, with expiration beginning in 2034 [344]. - The company may incur substantial costs related to royalty payments for licenses obtained from third parties, negatively affecting financial results [340]. - The company has foreign NOL carryforwards of approximately $63.7 million and $63.3 million for Canadian and French tax purposes, respectively, with varying expiration timelines [344]. - Changes to Internal Revenue Code Section 174 require the company to capitalize and amortize research and development expenditures over five or 15 years, impacting NOL utilization [346]. - The company has never paid dividends on its capital stock and does not anticipate doing so in the foreseeable future, intending to retain earnings for business growth [353]. - The company’s quarterly operating results may fluctuate significantly due to various factors, including reimbursement and market conditions, which could affect stock price [354]. - The company’s ability to use NOL carryforwards may be limited by changes in corporate ownership, potentially resulting in increased future tax liability [345]. - The company recognizes test revenue upon delivery of patient reports, which may lead to fluctuations in revenue and impact financial results [357]. Research and Development - The company is focused on developing enhancements to its test offerings and additional diagnostic tests, requiring significant resources for research and development [279]. - The product development process involves high risks, with many projects failing to result in commercial products, potentially delaying revenue generation [280]. - The company faces challenges in obtaining sufficient samples for clinical studies, which could hinder product development and reimbursement [280]. - Rapid technological advancements in diagnostics necessitate continuous innovation to maintain competitive positioning and prevent obsolescence [281]. Data Privacy and Cybersecurity - The company faces risks related to cybersecurity, including potential breaches that could compromise sensitive data and harm its reputation [299]. - Compliance with evolving data privacy laws, such as GDPR, may require operational changes and could lead to financial penalties for noncompliance [306]. - The company may incur additional costs and risks due to the complexities of data protection laws in the UK following Brexit [308]. - The company is subject to various federal and state laws in the US regarding the protection of health-related and personal information, which could result in civil and criminal penalties if violated [309]. - The CCPA and CPRA impose increased privacy and data security obligations, potentially raising compliance costs and liabilities for the company [310]. - The company may face additional compliance costs and complexities due to international data transfer restrictions and local data residency laws in countries like Brazil and China [312]. - The evolving interpretation of consumer and data protection laws could lead to unexpected compliance costs and government-imposed fines [313]. - The C2i Acquisition involves personal data that may be subject to various privacy laws, increasing the complexity of global data compliance obligations [314].

Veracyte, Inc. (NASDAQ: VCYT ) , a prominent company in the field of genomic diagnostics, headquartered, incidentally, in South San Francisco, has made a name for itself by developing cutting-edge yet minimally invasive tests, the kind that, crucially, help improve patient outcomes, particularly in oncology and a range ofThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences o ...

Veracyte (VCYT) delivered fourth-quarter 2024 earnings of 36 cents per share, which marked a stupendous improvement of 71.4% from the year-ago period’s figure of 21 cents. The bottom line beat the Zacks Consensus Estimate by 24.1%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The company-adjusted earnings per share (EPS) were 6 cents compared to the year-ago period’s loss of 39 cents per share. Full-year 2024 EPS of $1.19 increased 105.2% from the prior-year figure of 58 cents. Th ...